Neurolief's Proliv®Rx Gains Single Case Agreements for At-Home Depression Therapy

Neurolief's Breakthrough in Depression Treatment: The Proliv®Rx Story



In a significant development for mental health treatment, Neurolief has announced that they have successfully secured single case agreements with various payers in the United States for their flagship product, Proliv®Rx. This FDA-approved at-home brain neuromodulation therapy is designed specifically for adults grappling with major depressive disorder (MDD), who have not found sufficient relief from traditional antidepressant medications.

With these agreements in place, Neurolief is now able to accept prescriptions from all healthcare providers whose patients are in need of insurance coverage for this innovative treatment. This milestone marks a pivotal moment in the company's strategy to broaden access to Proliv®Rx, highlighting a promising pathway towards commercial reimbursement.

The Mechanism Behind Proliv®Rx


Proliv®Rx operates through a sophisticated, yet user-friendly mechanism involving External Combined Occipital and Trigeminal Afferent Stimulation (eCOT-AS). It leverages six electrodes and three independent channels to perform non-invasive stimulation of the occipital and trigeminal nerves, which play critical roles in mood regulation. Notably, the therapy does not require any invasive procedures, making it suitable for a broad range of patients.

The treatment regimen is structured over 8 to 16 weeks, with sessions lasting 40 minutes, carried out conveniently at home. Furthermore, a connected digital platform assists in remote monitoring and supports patients throughout their treatment journey, ensuring adherence and tracking of symptoms.

Bridging the Gap for Patients


Securing these agreements is a crucial step in expanding patient access to advanced therapy options. According to Scott Drees, CEO of Neurolief, the company aims to simplify this process for both patients and their healthcare providers. By collaborating directly with insurance companies and clinicians, Neurolief is advocating for patients, from establishing medical necessity to navigating potential appeals for denied requests.

Dr. Owen Muir, Chief Medical Officer at Neurolief, emphasizes the impact of this approach: “For patients who struggle to find relief through traditional antidepressants, traveling to specialized treatment centers for advanced options can be an immense challenge. Proliv®Rx not only introduces a clinically validated therapy into the comfort of one's home but also provides a medically supervised regimen that fosters accountability and support.”

An Encouraging Outlook Based on Research


The announcement also draws attention to the impressive outcomes from a pivotal clinical trial known as the MOOD study. This randomized, double-blind, sham-controlled trial included 124 adults battling MDD, who experienced notable improvements with Proliv®Rx compared to sham treatment. After 16 weeks, nearly 32% of participants on active treatment reached remission, which significantly underscores the therapy's efficacy.

As reported by the National Institute of Mental Health, about 21 million adults in the U.S. suffered at least one major depressive episode within the past year. Alarmingly, approximately one-third of patients with MDD do not respond adequately to traditional antidepressants, highlighting an urgent need for innovative solutions like Proliv®Rx.

Expanding Access Beyond the Commercial Sphere


Neurolief is actively pursuing a comprehensive market-access strategy that spans not just commercial payers but also health systems and the U.S. Department of Veterans Affairs. This inclusive approach underscores Neurolief's commitment to ensuring widespread accessibility and the potential for improved mental health outcomes for diverse patient populations.

About Neurolief


Founded with the mission to close critical gaps in mental health care, Neurolief is pioneering neuromodulation therapies tailored for mental and neurological disorders. With a strong focus on clinical validation and real-world accessibility, Neurolief stands at the forefront of innovation in mental health, transforming the lives of individuals suffering from conditions like MDD.

In summary, Neurolief's breakthrough with Proliv®Rx signifies not only a technological advancement in treating depression but also a hopeful development for millions who are seeking effective and accessible mental health solutions.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.